Independent labs report that rapamycin extends mouse lifespan and decreases cellular senescence in cells, although some senescence results point the other way. A human trial reports improved general health; another reports no clear walking-distance improvement and impaired chair stands. Some human papers declare developer ties, and companies developing these drugs sponsor trials across uses.
2,045 findings in 932 papers from 2002 to 2026, 85 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 338 independent labs in 48 countries; 1,344 trials, 35 about aging, 474 with no results posted.
“angioplasty with sirolimus-coated balloons led to a lower incidence of major adverse limb events at 1 year than angioplasty with uncoated balloons”
Cells, worms or flies, mice and humans: replicated by independent labs.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
338 independent labs in 48 countries
114 findings against
1,344 trials, 35 about aging, 474 with no results posted
↓down: Decreases approximate protrusion volume−61.556 units; P < .001
Randomized trial12 weeks
65 peopleHyperplastic rosacea
Journal of the American Academy of Dermatology, Nov 10, 2026
↑up: Increases total cholesterolWeek 18 total cholesterol: 236.0 versus 219.6 mg/dl; LDL cholesterol: 151.7 versus 136.8 mg/dl; triglycerides: 159.4 versus 133.2 mg/dl
↑up: Increases C-reactive protein
↓down: Decreases hemoglobin-related parameters
Randomized trial18 weeks
63 peopleALS
Frontiers in pharmacology, Oct 30, 2026
↑up: Improves clinical response3 months: 4/5 (80%; 95% CI 28–99); 12 months: 3/4 evaluable (75%; 95% CI 19–99)
Treated cohort3 and 12 months
5 peopleAdd-on treatment for active refractory iMCD-TAFRO
DrugAge records 22 results from 15 papers: 8 in C. elegans, 8 in mice and 6 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.
Rapamycin extends lifespan in flies (brewer's yeast medium; extended lifespan in eight experiments) (beneficial in eight experiments; neutral in 14).
“On a nutrient-rich brewer's yeast medium favored by 4/5 strains for egg-laying, rapamycin was beneficial in eight, neutral in 14 and not significantly harmful in any experiment.”
Model organismsbrewer's yeast medium; extended lifespan in eight experiments
Rapamycin shortens lifespan in flies (cornmeal/torula yeast medium; shortened lifespan in 19 experiments) (harmful in 19 experiments; no effect in 6; extended in 1).
“On a cornmeal/torula yeast-based medium, rapamycin extended life in one experiment, had no effect in six and was harmful in 19.”
Model organismscornmeal/torula yeast medium; shortened lifespan in 19 experiments
Rapamycin extends lifespan in worms (encapsulated in PEG-coated albumin nanoparticles; compared with free rapamycin) (~70% lifespan extension; outperforms free rapamycin).
“NPA-RAP did not affect fat content but extended lifespan by ∼70%, outperforming free rapamycin.”
Model organismsencapsulated in PEG-coated albumin nanoparticles; compared with free rapamycinPEG-coated albumin nanoparticles (NPA-RAP)
↓downin human cells12↓downin cells4↓downin mice3↓downin mouse cells3+6
30 studies
Rapamycin decreases cellular senescence in vivo.
“Overall, these results suggest that rapamycin reduces the expression of immune exhaustion markers, and p21, a marker of both persistent DNA damage and cell senescence.”
Rapamycin was not clearly linked with cellular senescence in humans (at target GVHD-prophylaxis doses, compared with cyclosporine plus MMF cohort).
“neither expression of senescence markers nor the abundance of SASP factors differed significantly in the sirolimus treated cohort compared to cyclosporine control cohort”
Humansat target GVHD-prophylaxis doses, compared with cyclosporine plus MMF cohorttarget doses to reduce GVHD risk
“One month of rapamycin treatment effectively suppressed mTOR signaling and reduced cellular senescence, inflammation, fibrosis, and oxidative damage in the ovary, lung, small intestine, and skeletal muscle.”
Animalsovary, lung, small intestine, skeletal muscleone month
↑upin mice6↑upin human cells5↑upin reviews5↓downin bovine cells1+5
22 studies
Rapamycin activates autophagy in human cells.
“At the molecular level, rapamycin suppressed mTOR expression and increased the mRNA and protein expression of Beclin-1 and LC3B, indicating activation of autophagy-related signaling.”
Rapamycin activates autophagy (via suppression of mTOR signalling in preclinical studies).
“Preclinical studies have shown that rapamycin can stimulate autophagic pathways by suppressing mTOR signalling, leading to increased expression of autophagy markers.”
Reviewvia suppression of mTOR signalling in preclinical studies
↓downin human cells3↓downin humans2↓downin reviews2↓downin mice1+2
10 studies
Rapamycin decreases inflammation in humans (APOE4 carriers).
“shows that the E4(+) group exhibited significant post-treatment reductions in monocyte chemoattractant protein-1 (MCP-1), a key mediator of inflammation and tissue injury (−0.155; 95% CI: −0.307, −0.003, p = 0.046).”
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·
Rapamycin decreases inflammation in APOE4 carriers.
“shows that the E4(+) group experienced significant post-treatment reductions in monocyte chemoattractant protein-1 (MCP-1), a key regulator of inflammation and tissue damage.”
“Animal studies confirmed rapamycin's role in alveolar bone preservation, inhibition of biofilm formation, immune modulation, and periodontal inflammation attenuation.”
Rapamycin improves cognitive function in mice (older mice undergoing anesthesia and surgery) (β 54.51, 95% CI 6.77–102.25).
“improved cognitive performance at 1-week postoperatively (β 40.18, 95%C.I. 8.70-71.67, p = 0.012), but only in older mice (β 54.51, 95%C.I. 6.77-102.25, p = 0.025).”
Animalsolder mice undergoing anesthesia and surgery1 week postoperatively after 8 weeks of preoperative treatmentn = 20
“Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity in diverse model organisms.”
Rapamycin showed no clear effect on mortality in humans (primary safety outcome, death from any cause within 1 year) (risk difference -1.0 percentage points (95% CI -4.6 to 2.7); P = 0.67).
“Death occurred in 74 patients (11.8%) in the sirolimus-coated-balloon group and in 80 patients (12.8%) in the uncoated-balloon group”
Human trialprimary safety outcome, death from any cause within 1 yearsirolimus-coated balloon1 yearn = 1,252
Rapamycin increases total cholesterol in humans (ALS; compared with placebo) (Week 18 total cholesterol: 236.0 versus 219.6 mg/dl; LDL cholesterol: 151.7 versus 136.8 mg/dl; triglycerides: 159.4 versus 133.2 mg/dl).
“In the rapamycin-treated patients, total and LDL cholesterol, and triglycerides rose compared to placebo”
Human trialALS; compared with placebo1 or 2 mg/m2/day18 weeksn = 63
Rapamycin analogs increase total cholesterol in individuals with ageing-related diseases.
“there were increased numbers of infections and increases in total cholesterol, LDL cholesterol, and triglycerides in individuals with ageing-related diseases”
Rapamycin inhibits senescence-associated secretory phenotype (SASP) in humans.
“Given that p16 and COX2 play a key role in cellular senescence and inflammation respectively, their significant reduction after sirolimus treatment appears to indicate an attenuated SASP and inflammatory response, which should contribute to the anti-malignant activity of sirolimus.”
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·
Rapamycin increases cerebral blood flow in humans (APOE4 carriers).
“After 4 weeks of rapamycin treatment, CBF was increased in the overall study sample (3.08; 95% CI: 0.16, 6.00, p = 0.04), particularly E4(+) participants, who showed a significant increase in CBF (4.68; 95% CI: 0.003, 9.36, p = 0.05).”
Rapamycin improves cerebral blood flow in APOE4 carriers (>15%).
“Results indicate that the Rapamycin regimen significantly increased CBF in APOE4 carriers (E4(+)). displays CBF maps for both E4(+) and E4(−) before and after the intervention, with the color bar representing CBF values from 0 to 65 ml/100g/min on a linear scale.”
Rapamycin is associated with NETosis-associated markers in mice (bone cancer pain mouse model).
“rapamycin treatment was associated with reduced levels of NETosis-associated markers, including NE, MPO, and citrullinated histone H3, in the spinal cord.”
Animalsbone cancer pain mouse modelspinal cord5 mg/kg
Rapamycin is associated with inflammatory monocyte and B cell abundance in humans (TAFRO-phenotype patient receiving add-on treatment; exploratory paired analysis).
“Exploratory paired single-cell RNA sequencing in one TAFRO-phenotype patient showed reductions in inflammatory monocytes and B cells with lower cytotoxic and proliferative programs.”
Independent labs report mouse lifespan extension with rapamycin, but also shortening, and reduced senescence in human cells. Human trials report improved general health but mixed physical-function outcomes. Of registered trials, 28 concern aging; across all uses, 473 ended over a year ago without posted results or citing papers, and 361 are developer-sponsored.
Summary rewritten as its findings changed.
As it read before
Independent labs report longer mouse lifespans with rapamycin but also reproduce lifespan shortening; other mouse studies find no change. Human trials report improved general health but mixed physical-function outcomes. Of registered trials, 26 concern aging; across all indications, 474 ended over a year ago without posted results or citing papers, 380 have developer sponsors, and four human papers declare Novartis ties.
Summary rewritten as its findings changed.
As it read before
Independent labs report that rapamycin extends mouse lifespan, but also replicate lifespan shortening. A human trial reports improved lean tissue mass in women receiving 10 mg weekly. Of registered trials, 25 concern aging; across all uses, 474 ended over a year ago without posted results or citing papers, and 380 have developer sponsors.
Summary rewritten as its findings changed.
As it read before
Independent labs report both lifespan extension and shortening in rapamycin-treated mice; other mouse studies report no lifespan effect. Independent labs also report improved cognition with everolimus in humans. Trial registrations include 19 about aging; across all uses, 401 trials ended over a year ago without posted results or citing papers, and some papers declare company ties.
Summary rewritten as its findings changed.
As it read before
Independent labs report rapamycin extending mouse lifespan; fly lifespan results differ, and everolimus induces mouse senescence. A human trial reports topical rapamycin reducing skin p16INK4a; 19 trials concern aging, while 400 across all uses ended over a year ago without posted results or papers citing them. Some trials are developer-sponsored.
Tested across 20 independent fibroblast datasets, ECMExplainer used gene-activity comparisons to distinguish cell states and capture several processes related to aging.Tested across 20 independent fibroblast datasets, ECMExplainer used gene-activity comparisons to distinguish cell states and capture several processes related to aging.
In cell experiments, kidney-risk protein variants entered an internal membrane more readily than the comparison variant, while rapamycin reduced protein levels and cell…In cell experiments, kidney-risk protein variants entered an internal membrane more readily than the comparison variant, while rapamycin reduced protein levels and cell harm.